EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 6019 participants.
Also called NCT05284747
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 6,019 participants
- Sponsor
- Registry
-
NCT05284747 -
2021-005272-19
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Brazil, Sweden
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05284747. Randomized; no masking; primary purpose treatment. Start 2022-10-26 (actual); primary completion 2027-05-29 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
- Acronym
- EVOLVE-MI
- Condition
- Cardiovascular Disease
- Condition
- Myocardial Infarction
- Condition
- Stroke
- Condition
- Coronary Revascularization
- Intervention (Drug)
- Evolocumab
- Intervention (Drug)
- Routine Lipid Management
- Lead sponsor
- Amgen
- Collaborator
- Colorado Prevention Center
Record details
- Record id
cardio:ct-nct05284747- Content hash
d0e206266deddf0edb4925383b09b4078006deb77bf48caa86d92c514d21055d